An important training aid for your nursing skills lab, EMT field training simulations, and more
The Regulatory Reality: FDA and WADA, Stated Plainly Regulatory status is a hard fact, not a matter of interpretation, so it deserves a plain-language section
Semaglutide, tirzepatide, BPC-157, TB-500, and all growth hormone peptides use the same starting dose regardless of body weight
What people run, how stacking works for fat loss, and how to build your own protocol
Melanotan-1 (afamelanotide/Scenesse) is the only EMA-approved treatment for EPP, with Phase 3 RCT data showing increased pain-free sun exposure and improved quality of life
Key Implementation Points Standard monotherapy escalates from 0.3 mg to 4.5 mg weekly over 20 weeks Combination therapy (CagriSema) reaches maintenance at cagrilintide 2.4 mg plus semaglutide 2.4 mg weekly Gradual escalation minimizes gastrointestinal side effects and allows metabolic adaptation Individual adjustment based on tolerance and response optimizes outcomes Proper administration technique and site rotation ensure consistent absorption Comprehensive monitoring tracks both efficacy markers and safety parameters Actionable Next Steps For fitness instructors and health coaches : Develop educational materials explaining peptide therapy basics to help clients make informed decisions about emerging metabolic health approaches